China: Commercial health insurance trends

While the National Reimbursement Drug List (NRDL) continues to be the dominant path to public reimbursement in China, commercial health insurance (CHI) in China is quickly emerging as an alternative reimbursement option.

Germany: How the GKV-FinStG law is transforming the pharma P&R landscape

In November 2022, the new GKV Financial Stabilization Act (GKV-FinStG) came into effect after being passed by the German parliament.

UK: Integrated Care Systems – lessons and outlook from the first six months

In July 2022, Integrated Care Systems (ICSs) became the statutory bodies responsible for commissioning medicines and budget allocation, replacing Clinical Commissioning Groups (CCGs).

Spain: Pharmaco-economic analyses and their implications

Pharmaco-economic analyses are gaining momentum in Spain, but what are the potential implications?

Better Health: Let’s rethink healthcare

From new vaccines to lifestyle apps, smart watches, and weight loss therapies – the opportunities for healthcare to deliver more value seem endless.

How Dutch B2B companies prepare for uncertain economic times

How and when to use bundle pricing as part of your strategy

A successful bundle pricing strategy has the potential to increase revenue and customer reach. But when should you use it and how do you make sure it’s a success? 

Six growth topics for the CCO agenda in 2023

Pathway to success in SME banking

Our recent study reveals SMEs in Australia are turning to third parties and away from their current financial providers. We share our proven approach for financial institutions to better meet SME needs.